A decision analysis to determine the appropriate treatment for low-risk myelodysplastic syndromes.

被引：0
|
作者：
Sekeres, MA [1 ]
Fu, AZ [1 ]
Maciejewski, JP [1 ]
Golshayan, AR [1 ]
Kalaycio, M [1 ]
Kattan, MW [1 ]
机构：
[1] Cleveland Clin Fdn, Cleveland, OH 44195 USA
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2533
引用
收藏
页码：711A / 711A
页数：1
相关论文
共 50 条
  • [41] Hypochromic red blood cells in low-risk myelodysplastic syndromes:: effects of treatment with hemopoietic growth factors
    Ljung, T
    Bäck, R
    Hellström-Lindberg, E
    HAEMATOLOGICA, 2004, 89 (12) : 1446 - 1453
  • [42] Angiogenesis in myelodysplastic syndromes. Analysis of 59 cases.
    Pruneri, G
    Soligo, D
    Carboni, N
    Lambertenghi-Deliliers, G
    Cortelezzi, A
    Pezzella, F
    Bertolini, F
    BLOOD, 1998, 92 (10) : 715A - 715A
  • [43] An accessible patient-derived xenograft model of low-risk myelodysplastic syndromes
    Teodorescu, Patric
    Pasca, Sergiu
    Choi, Inyoung
    Shams, Cynthia
    Dalton, W. Brian
    Gondek, Lukasz P.
    DeZern, Amy E.
    Ghiaur, Gabriel
    HAEMATOLOGICA, 2024, 109 (01) : 337 - 342
  • [44] Moving low-risk myelodysplastic syndromes from humans to mice: is it truly that simple?
    Coriu, Daniel
    Stancioaica, Maria -Camelia
    HAEMATOLOGICA, 2024, 109 (01) : 8 - 10
  • [45] The Management of Low-Risk Myelodysplastic Syndromes-Current Standards and Recent Advances
    Randall, Michael P.
    DeZern, Amy E.
    CANCER JOURNAL, 2023, 29 (03): : 152 - 159
  • [46] Luspatercept: a candidate to dethrone erythropoietin in first line in low-risk myelodysplastic syndromes?
    Robert-Van Houtteghem, Tristan
    HEMATOLOGIE, 2023, 29 (05): : 269 - 271
  • [47] HEPCIDIN AND ERYTHROFERRONE (ERFE) ARE NOT CORRELATED IN THE ANEMIA OF LOW-RISK MYELODYSPLASTIC SYNDROMES (MDS)
    Redondo, S.
    Oarbeascoa, G.
    Moran Jimenez, M. J.
    Domingo, A.
    Munoz Linares, C.
    Moreno Carralero, M. I.
    Bellon, J. M.
    Del Campo Rincon, J. F.
    Diez-Martin, J. L.
    Font, P.
    HAEMATOLOGICA, 2018, 103 : 183 - 184
  • [48] Efficacy of growth factors compared to other therapies for low-risk myelodysplastic syndromes
    Golshayan, Ali-Reza
    Jin, Tao
    Maciejewski, Jaroslaw
    Fu, Alex Z.
    Bershadsky, Boris
    Kattan, Michael W.
    Kalaycio, Matt E.
    Sekeres, Mikkael A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2007, 137 (02) : 125 - 132
  • [49] Myelodysplastic syndromes. Epidemiology, molecular and morphological characteristics and risk stratification
    Schmitt-Graeff, A. H.
    Mueller, M. J.
    Fisch, P.
    PATHOLOGE, 2013, 34 (01): : 45 - 55
  • [50] Pilot study of low dose melphalan and bortezomib for treatment of acute myelogenous leukemia and high-risk myelodysplastic syndromes.
    Bubis, JA
    Ely, P
    Meehan, KR
    Stearns, D
    Schaal, AD
    Kimtis, EA
    Lowrey, C
    Bengtson, EM
    Hill, J
    Gautier, M
    BLOOD, 2005, 106 (11) : 237B - 237B
12345